BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 32865948)

  • 21. Predictive Factors of Recurrence in Patients with Pathological Complete Response After Esophagectomy Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Study.
    Luc G; Gronnier C; Lebreton G; Brigand C; Mabrut JY; Bail JP; Meunier B; Collet D; Mariette C
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1357-64. PubMed ID: 26014152
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Validity of upfront surgery for patients with unsuspected lymph node metastasis in esophageal cancer: a propensity scoring matching study.
    Park JK; Kim JJ; Moon SW; Cho DG
    J Cardiothorac Surg; 2018 Jun; 13(1):62. PubMed ID: 29880029
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Lymph Node Yield on Overall Survival in Patients Treated With Neoadjuvant Chemoradiotherapy Followed by Esophagectomy for Cancer: A Population-based Cohort Study in the Netherlands.
    Visser E; van Rossum PSN; Ruurda JP; van Hillegersberg R
    Ann Surg; 2017 Nov; 266(5):863-869. PubMed ID: 28742691
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgery.
    Hamai Y; Hihara J; Emi M; Furukawa T; Murakami Y; Nishibuchi I; Ibuki Y; Yamakita I; Kurokawa T; Nagata Y; Okada M
    World J Surg; 2018 May; 42(5):1496-1505. PubMed ID: 29030675
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between time interval from neoadjuvant chemoradiotherapy to surgery and complete histological tumor response in esophageal and gastroesophageal junction cancer: a national cohort study.
    Klevebro F; Nilsson K; Lindblad M; Ekman S; Johansson J; Lundell L; Ndegwa N; Hedberg J; Nilsson M
    Dis Esophagus; 2020 May; 33(5):. PubMed ID: 31676895
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Salvage esophagectomy for locoregional failure after chemoradiotherapy in patients with advanced esophageal cancer.
    Yoo C; Park JH; Yoon DH; Park SI; Kim HR; Kim JH; Jung HY; Lee GH; Choi KD; Song HJ; Song HY; Shin JH; Cho KJ; Kim YH; Kim SB
    Ann Thorac Surg; 2012 Dec; 94(6):1862-8. PubMed ID: 22959577
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Salvage esophagectomy after failed definitive chemoradiation for esophageal adenocarcinoma.
    Marks JL; Hofstetter W; Correa AM; Mehran RJ; Rice D; Roth J; Walsh G; Vaporciyan A; Erasmus J; Chang J; Maru D; Lee JH; Lee J; Ajani JA; Swisher SG
    Ann Thorac Surg; 2012 Oct; 94(4):1126-32; discussion 1132-3. PubMed ID: 22921233
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment Modalities for Esophageal Adenocarcinoma in the United States: Trends and Survival Outcomes.
    Di Corpo M; Schlottmann F; Strassle PD; Nurczyk K; Patti MG
    J Laparoendosc Adv Surg Tech A; 2019 Aug; 29(8):989-994. PubMed ID: 31246532
    [No Abstract]   [Full Text] [Related]  

  • 29. Role of neoadjuvant chemoradiotherapy in clinical T2N0M0 esophageal cancer: A population-based cohort study.
    Goense L; Visser E; Haj Mohammad N; Mook S; Verhoeven RHA; Meijer GJ; van Rossum PSN; Ruurda JP; van Hillegersberg R
    Eur J Surg Oncol; 2018 May; 44(5):620-625. PubMed ID: 29478739
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neoadjuvant chemoradiation is associated with improved overall survival in older patients with esophageal cancer.
    Guttmann DM; Mitra N; Metz JM; Plastaras J; Feng W; Swisher-McClure S
    J Geriatr Oncol; 2018 Jan; 9(1):40-46. PubMed ID: 28887066
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of multimodality neoadjuvant therapy for esophageal cancer in the United States: assessment of 987 hospitals.
    Merkow RP; Bilimoria KY; McCarter MD; Chow WB; Ko CY; Bentrem DJ
    Ann Surg Oncol; 2012 Feb; 19(2):357-64. PubMed ID: 21769460
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patterns of Care in Neoadjuvant Chemoradiotherapy for Node-Positive Esophageal Adenocarcinoma.
    Raman V; Jawitz OK; Voigt SL; Rhodin KE; Kim AW; Tong BC; D'Amico TA; Harpole DH
    Ann Thorac Surg; 2020 Dec; 110(6):1832-1839. PubMed ID: 32622794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Postoperative Pneumonia is Associated with Long-Term Oncologic Outcomes of Definitive Chemoradiotherapy Followed by Salvage Esophagectomy for Esophageal Cancer.
    Takeuchi M; Kawakubo H; Mayanagi S; Yoshida K; Fukuda K; Nakamura R; Suda K; Wada N; Takeuchi H; Kitagawa Y
    J Gastrointest Surg; 2018 Nov; 22(11):1881-1889. PubMed ID: 29980971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study.
    Zhang X; Eyck BM; Yang Y; Liu J; Chao YK; Hou MM; Hung TM; Pang Q; Yu ZT; Jiang H; Law S; Wong I; Lam KO; van der Wilk BJ; van der Gaast A; Spaander MCW; Valkema R; Lagarde SM; Wijnhoven BPL; van Lanschot JJB; Li Z
    BMC Cancer; 2020 Mar; 20(1):194. PubMed ID: 32143580
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes for Esophageal Squamous Cell Carcinoma Treated with Curative Intent in a Western Cohort: Should Multimodal Therapy Be the Gold Standard?
    Sheil F; Donohoe CL; King S; O'Toole D; Cunningham M; Cuffe S; Ravi N; Reynolds JV
    World J Surg; 2018 May; 42(5):1485-1495. PubMed ID: 29075858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association Between Clinically Staged Node-Negative Esophageal Adenocarcinoma and Overall Survival Benefit From Neoadjuvant Chemoradiation.
    Gabriel E; Attwood K; Du W; Tuttle R; Alnaji RM; Nurkin S; Malhotra U; Hochwald SN; Kukar M
    JAMA Surg; 2016 Mar; 151(3):234-45. PubMed ID: 26559488
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Salvage esophagectomy after definitive chemoradiotherapy for thoracic esophageal cancer.
    Miyata H; Yamasaki M; Takiguchi S; Nakajima K; Fujiwara Y; Nishida T; Mori M; Doki Y
    J Surg Oncol; 2009 Nov; 100(6):442-6. PubMed ID: 19653262
    [TBL] [Abstract][Full Text] [Related]  

  • 38. No Survival Difference with Neoadjuvant Chemoradiotherapy Compared with Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: ResultsĀ from the National Cancer Data Base.
    Al-Sukhni E; Gabriel E; Attwood K; Kukar M; Nurkin SJ; Hochwald SN
    J Am Coll Surg; 2016 Dec; 223(6):784-792.e1. PubMed ID: 27641320
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Do We Need to Add Postoperative Radiotherapy in Patients Undergoing Trimodality Therapy for Esophageal Squamous Cell Carcinoma with Positive Lymph Nodes Disease?
    Huang PM; Hsu FM; Lin CC; Hsu CH; Cheng JC; Lee JM
    Dig Surg; 2018; 35(2):104-110. PubMed ID: 28675905
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT
    Tang H; Tan L; Shen Y; Wang H; Lin M; Feng M; Xu S; Guo W; Qian C; Liu T; Zeng Z; Hou Y; Yu Z; Jiang H; Li Z; Chen C; Lian C; Du M; Li H; Xie D; Yin J; Zhao N; Wang Q
    BMC Cancer; 2017 Jun; 17(1):450. PubMed ID: 28659128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.